Breaking News Instant updates and real-time market news.

ALNY

Alnylam

$72.83

-0.63 (-0.86%)

, MRK

Merck

$64.39

1.19 (1.88%)

07:33
06/12/17
06/12
07:33
06/12/17
07:33

USPTO issues allowances to Alnylam for two patent applications

Alnylam Pharmaceuticals (ALNY) announced that the U.S. Patent and Trademark Office has issued Notices of Allowance for two patent applications owned by Alnylam. The USPTO has allowed claims in patent application 15/483,354, which is a member of the McSwiggen patent family acquired from Merck (MRK) in 2014, covering single-stranded polynucleotides of about 18 to 20 nucleotides targeting the human transthyretin gene, and comprising 10 or more phosphorothioate linkages as well as 10 or more chemically modified pyrimidines. The second allowed patent application, 14/943,612, which is a member of the Manoharan patent family, contains claims directed to RNA agents of any length with at least one 2'-O alkyl modification and 4-20 phosphorothioate linkages conjugated to a GalNAc moiety of any valency.

ALNY

Alnylam

$72.83

-0.63 (-0.86%)

MRK

Merck

$64.39

1.19 (1.88%)

  • 14

    Jun

  • 22

    Sep

ALNY Alnylam
$72.83

-0.63 (-0.86%)

05/16/17
LEER
05/16/17
NO CHANGE
Target $67
LEER
Outperform
Alnylam price target raised to $67 from $53 at Leerink
Leerink analyst Paul Matteis expects yesterday's data from Ionis Pharmaceuticals (IONS) will put TTRrx at a commercial disadvantage to Alnylam's (ALNY) patisiran. The top-line results for TTRrx, which showed high efficacy and several safety issues, is the best case for Alnylam, Matteis tells investors in a research note. He raised his odds of approval for both programs but lowered his price target for Ionis to $45 from $47. Matteis has Market Perform ratings on both stocks.
05/16/17
PIPR
05/16/17
NO CHANGE
Target $69
PIPR
Overweight
Piper Jaffray sees positive readthrough for Prothena from Ionis data
Piper Jaffray analyst Steven Breazzano argues that investors should "take a closer look" at Prothena (PRTA) and its PRX004 product following the recent amyloid neuropathy data from Ionis Pharmaceuticals (IONS). Prothena's candidate is expected to enter the clinic in early 2018, and Breazzano argues that there is "room for differentiation" in the space, as the drug clears the protein buildup that characterizes amyloidosis rather than directly shutting off production, as with Ionis and Alnylam's (ALNY) approaches. "At a minimum," the analyst says, a deposit-clearing approach would be complementary to production-stopping drugs. Breazzano reiterates an Overweight rating on Prothena.
05/17/17
LTCO
05/17/17
NO CHANGE
Target $80
LTCO
Buy
Alnylam price target raised to $80 from $75 at Ladenburg
Ladenburg Thalmann analyst Christopher James raised his price target for Alnylam (ALNY) to $80 saying the NEURO-TTR data reported by Ionis Pharmaceuticals (IONS) are "quite positive" for patisiran and the upcoming APOLLO readout. The analyst reiterates a Buy rating on Alnylam shares.
05/24/17
PIPR
05/24/17
NO CHANGE
Target $116
PIPR
Overweight
Alnylam share offering a 'smart' move after rally, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff views Alnylam Pharmaceuticals' 5M share offering as "smart" following the recent share rally and ahead of Phase III data on patisiran in September. The analyst looks for the company to launch multiple orphan drugs including patisiran in 2018, fitusiran in hemophilia in 2019 and givosiran in porphyria in 2020. He lowered his price target for the shares to $116 from $118 and reiterates an Overweight rating on Alnylam.
MRK Merck
$64.39

1.19 (1.88%)

05/22/17
ADAM
05/22/17
NO CHANGE
Target $85
ADAM
Buy
CV events 'may kill' Amgen's romosozumab development, says Canaccord
Canaccord analyst John Newman said Amgen (AMGN) and partner UCB's report of a higher rate of cardiovascular Serious Adverse Events for romosozumab in the Phase 3 ARCH study in osteoporosis suggests a much lower chance of FDA approval for the drug and may "kill" romosozumab's development. He notes that Merck's (MRK) cathepsin-K inhibitor was previously discontinued due to increased risk of atrial fibrillation and stroke. In addition to the safety signals, Newman points out that romosozumab was worse than Radius' (RDUS) Tymlos for non-vertebral fracture and for vertebral fracture, suggesting Radius' drug also has much better efficacy, said the analyst, who keeps a Buy rating and $85 price target on Radius Health shares, which are up $4.47, or 12.8%, to $39.40 in pre-market trading.
06/05/17
PIPR
06/05/17
NO CHANGE
PIPR
Piper views AstraZeneca, J&J as ASCO standouts
The standouts at ASCO over the weekend were the "compelling results" presented on Johnson & Johnson's (JNJ) Zytiga from the Latitude study in prostate cancer and AstraZeneca's (AZN) Lynparza in the OlympiAD trial in BRCA mutant breast cancer, Piper Jaffray analyst Richard Purkiss tells investors in a research note. In lung cancer, Merck's (MRK) updated data in KN021G "appears more promising" than Bristol-Myers' (BMY) updated data in CM012, the analyst adds. Purkiss believes, however, that relative to recent ASCOs, the data "so far in totality is underwhelming."
06/06/17
WELS
06/06/17
NO CHANGE
WELS
Amazon may be the next threat to drug pricing, says Wells Fargo
After CNBC recently reported that Amazon (AMZN) is considering going into the prescription pharmacy business in the U.S., Wells Fargo surveyed nearly 2,900 U.S. adults and found that 54% of those polled said they would use or would probably use "Amazon Pharmacy." While the e-commerce giant has not confirmed its U.S. pharmacy interest, if it did enter the market analyst David Maris believes it could see fast adoption and "usher in a new age of price transparency." Maris also wonders if pharmacy "may be just the beginning" and if Amazon eyes the "even larger prize" of fully integrated digital healthcare. Publicly traded large-cap pharmaceuticals companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded retail pharmacy operators include CVS Health (CVS), Walgreens (WBA), Fred's (FRED) and Rite Aid (RAD).
06/06/17
BMOC
06/06/17
NO CHANGE
BMOC
Incyte should be bought on recent weakness, says BMO Capital
BMO Capital analyst M. Ian Somaiya says that data on the combination of Bristol-Myers' (BMY) Opdivo and Incyte's (INCY) epacadostat "confirmed the benefit" seen in a previous study. The analyst says that the safety of Merck's (MRK) Keytruda in combination with epacadostat is better than the standard of care. He keeps a $166 price target and Outperform rating on Incyte.

TODAY'S FREE FLY STORIES

BXP

Boston Properties

$122.03

-0.4 (-0.33%)

07:46
08/17/17
08/17
07:46
08/17/17
07:46
Downgrade
Boston Properties rating change  »

Boston Properties…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LFC

China Life Insurance

$15.24

0.04 (0.26%)

07:46
08/17/17
08/17
07:46
08/17/17
07:46
Downgrade
China Life Insurance rating change  »

China Life Insurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSY

Hershey

$106.04

0.14 (0.13%)

07:46
08/17/17
08/17
07:46
08/17/17
07:46
Upgrade
Hershey rating change  »

Hershey upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RVLT

Revolution Lighting

$6.82

-0.03 (-0.44%)

07:42
08/17/17
08/17
07:42
08/17/17
07:42
Hot Stocks
Revolution Lighting awarded DoD contract »

Revolution Lighting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOLD

Amicus

$12.60

0.31 (2.52%)

, IRWD

Ironwood

$14.92

0.06 (0.40%)

07:42
08/17/17
08/17
07:42
08/17/17
07:42
Recommendations
Amicus, Ironwood, Otonomy, Sarepta, Ignyta analyst commentary  »

JPMorgan lists top SMID…

FOLD

Amicus

$12.60

0.31 (2.52%)

IRWD

Ironwood

$14.92

0.06 (0.40%)

OTIC

Otonomy

$19.35

-0.1 (-0.51%)

SRPT

Sarepta

$37.43

0.72 (1.96%)

RXDX

Ignyta

$9.80

0.1 (1.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

  • 26

    Sep

CSVI

Computer Services

$46.50

0.45 (0.98%)

07:41
08/17/17
08/17
07:41
08/17/17
07:41
Hot Stocks
Computer Services announces retirement of president R. Stanley Eckenberg »

Computer Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROIC

Retail Opportunity

$20.14

0.09 (0.45%)

07:40
08/17/17
08/17
07:40
08/17/17
07:40
Upgrade
Retail Opportunity rating change  »

Retail Opportunity…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BABA

Alibaba

$159.50

1.75 (1.11%)

07:39
08/17/17
08/17
07:39
08/17/17
07:39
Hot Stocks
Alibaba: 'The numbers speak for themselves' »

Alibaba said on its Q2…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

  • 18

    Aug

AAPL

Apple

$160.94

-0.68 (-0.42%)

07:38
08/17/17
08/17
07:38
08/17/17
07:38
Periodicals
Apple Watch may not support voice calls at launch, AI reports »

The new LTE-connected…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

WMT

Wal-Mart

$80.98

0.21 (0.26%)

07:35
08/17/17
08/17
07:35
08/17/17
07:35
Hot Stocks
Breaking Hot Stocks news story on Wal-Mart »

Wal-Mart drops 2.3% in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

  • 16

    Nov

  • 20

    Feb

TDOC

Teladoc

$30.05

-1.15 (-3.69%)

07:35
08/17/17
08/17
07:35
08/17/17
07:35
Recommendations
Teladoc analyst commentary  »

Teladoc to benefit from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

  • 06

    Sep

  • 11

    Sep

AERI

Aerie Pharmaceuticals

$52.20

-0.2 (-0.38%)

07:35
08/17/17
08/17
07:35
08/17/17
07:35
Recommendations
Aerie Pharmaceuticals analyst commentary  »

Aerie Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 20

    Sep

  • 28

    Feb

BABA

Alibaba

$159.50

1.75 (1.11%)

, MU

Micron

$30.69

1.01 (3.40%)

07:35
08/17/17
08/17
07:35
08/17/17
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

BABA

Alibaba

$159.50

1.75 (1.11%)

MU

Micron

$30.69

1.01 (3.40%)

FCX

Freeport McMoRan

$14.77

0.8 (5.73%)

VALE

Vale

$10.10

0.32 (3.27%)

RIG

Transocean

$7.58

-0.33 (-4.17%)

MPC

Marathon Petroleum

$51.06

-0.83 (-1.60%)

COTY

Coty

$19.67

0.11 (0.56%)

PAGP

Plains GP Holdings

$20.35

-0.46 (-2.21%)

ETSY

Etsy

$15.60

-0.04 (-0.26%)

FOLD

Amicus

$12.60

0.31 (2.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

  • 18

    Aug

  • 22

    Aug

  • 29

    Aug

  • 29

    Aug

  • 06

    Sep

  • 08

    Nov

REG

Regency Centers

$65.52

0.46 (0.71%)

07:34
08/17/17
08/17
07:34
08/17/17
07:34
Upgrade
Regency Centers rating change  »

Regency Centers upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COMM

CommScope

$32.85

0.01 (0.03%)

07:34
08/17/17
08/17
07:34
08/17/17
07:34
Upgrade
CommScope rating change  »

CommScope upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

MSG

Madison Square Garden

$217.42

1.33 (0.62%)

07:33
08/17/17
08/17
07:33
08/17/17
07:33
Earnings
MSG reports Q4 EPS ($3.58), may not compare to consensus ($1.39) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

ARAY

Accuray

$4.00

-0.1 (-2.44%)

07:32
08/17/17
08/17
07:32
08/17/17
07:32
Hot Stocks
Accuray's Radixact system used by Summit Cancer Center-Boise for the first time »

Accuray and the Summit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

AMOV

America Movil, also tag AMX

$18.51

-0.07 (-0.38%)

, AMX

America Movil, also tag AMOV

$18.82

0.22 (1.18%)

07:32
08/17/17
08/17
07:32
08/17/17
07:32
Periodicals
Mexican Supreme Court rules for America Movil on interconnection fees, WSJ says »

Mexico's Supreme…

AMOV

America Movil, also tag AMX

$18.51

-0.07 (-0.38%)

AMX

America Movil, also tag AMOV

$18.82

0.22 (1.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDEN

Golden Entertainment

$21.41

0.23 (1.09%)

07:31
08/17/17
08/17
07:31
08/17/17
07:31
Hot Stocks
Golden Entertainment completes syndication of financing to fund American deal »

Golden Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBR

Petrobras

$8.65

0.06 (0.70%)

, CBI

CB&I

$9.97

-1.22 (-10.90%)

07:30
08/17/17
08/17
07:30
08/17/17
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

PBR

Petrobras

$8.65

0.06 (0.70%)

CBI

CB&I

$9.97

-1.22 (-10.90%)

URBN

Urban Outfitters

$19.76

2.94 (17.48%)

CL

Colgate-Palmolive

$71.93

0.13 (0.18%)

AXON

Axovant Sciences

$21.80

-0.83 (-3.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Aug

CSCO

Cisco

$32.34

0.25 (0.78%)

07:28
08/17/17
08/17
07:28
08/17/17
07:28
Recommendations
Cisco analyst commentary  »

Cisco stock likely range…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

LB

L Brands

$38.95

0.5 (1.30%)

07:28
08/17/17
08/17
07:28
08/17/17
07:28
Recommendations
L Brands analyst commentary  »

L Brands share losses may…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

CSCO

Cisco

$32.34

0.25 (0.78%)

07:28
08/17/17
08/17
07:28
08/17/17
07:28
Recommendations
Cisco analyst commentary  »

Cisco 'slowly moving…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

CCL

Carnival

$68.87

0.16 (0.23%)

07:28
08/17/17
08/17
07:28
08/17/17
07:28
Recommendations
Carnival analyst commentary  »

Carnival price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QTNA

Quantenna Communications

$17.79

-0.23 (-1.28%)

07:27
08/17/17
08/17
07:27
08/17/17
07:27
Conference/Events
Quantenna Communications management to meet with Deutsche Bank »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

  • 23

    Aug

  • 12

    Sep

  • 08

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.